fludarabine phosphate + mitoxantrone

**Fludarabine phosphate + mitoxantrone** is a combination chemotherapy regimen used primarily in the treatment of hematologic malignancies such as low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. - **Fludarabine phosphate** is a purine analogue antimetabolite that inhibits DNA synthesis by interfering with enzymes such as DNA polymerase alpha, ribonucleotide reductase, and DNA primase. It is converted intracellularly to its active triphosphate form, which incorporates into DNA and destabilizes the DNA molecule, leading to apoptosis[2][8]. - **Mitoxantrone** is a synthetic anthracenedione that acts as a DNA-reactive agent by intercalating into DNA, causing crosslinks and strand breaks, as well as inhibiting topoisomerase II. Mitoxantrone also exerts broad cytotoxic and immunosuppressive effects by impairing proliferation and function of T cells, B cells, and macrophages[4][6]. The combination produces additive or synergistic antineoplastic effects, resulting in high remission rates in advanced, low-grade lymphomas. Clinical data indicate efficacy with acceptable toxicity profiles, primarily myelosuppression and risk of infection[3][5].

Other names

fludarabine + mitoxantroneFN regimen